Patent intelligence · US
US 6054449
Compounds and method for PDT of intimal hyperplasia and other diseases
Compounds and method for PDT of intimal hyperplasia and other diseases
Patent details — US 6054449
- Jurisdiction
- US
- Status
- expired
- Grant date
- Apr 25, 2000
- Expiration
- Apr 20, 2020
- Applicant
- Miravant Pharmaceuticals, Inc.
- Claims
- 11
- CPC classes
- A61K, A61K41/0066, A61K41/0071, A61P
Quick answer
US 6054449 (Compounds and method for PDT of intimal hyperplasia and other diseases) is held by Miravant Pharmaceuticals, Inc.. Status: expired. Granted Apr 25, 2000. Expires Apr 20, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Miravant Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K41/0066, A61K41/0071, A61P, A61P17/06, A61P27/06
More from Miravant Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 6054449?
US 6054449 (Compounds and method for PDT of intimal hyperplasia and other diseases) is held by Miravant Pharmaceuticals, Inc.. Status: expired. Granted Apr 25, 2000. Expires Apr 20, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6054449?
Miravant Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 6054449 expire?
Our index shows an expiration date of Apr 20, 2020 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.